Switch to Health Care Professionals
Print PageWelcome to Genentech Rheumatology™ Access Solutions™
At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.
For more than 20 years, Genentech has demonstrated its commitment to assisting eligible patients whose financial situations may be a barrier to accessing our medicines.
For patients and their health care providers, Genentech Rheumatology Access Solutions provides:
Our specialists are passionate about helping patients access our medicines and exploring every possible solution to coverage or reimbursement issues.
Access and reimbursement issues can be confusing and challenging. Genentech Rheumatology Access Solutions is here to make the process as easy as possible.
Click on one of the icons below for the medicine that interests you, and find out how Genentech Rheumatology Access Solutions can help you and your health care providers with issues that may affect access and reimbursement.
At Genentech Rheumatology Access Solutions, we work hard to make information you need about coverage and reimbursement easily available 24 hours a day — either by phone at (866) 681-3261 between the hours of 6 a.m. and 5 p.m. PST Monday through Friday or 24/7 through our website. When you call Genentech Rheumatology Access Solutions, you will connect with one of our experts, whose sole job is to make sure that you get the coverage or reimbursement help you need.
ACTEMRA (tocilizumab) Important Safety Information
This information does not take the place of talking to your healthcare provider about either your medical condition or your treatment with ACTEMRA. Talk with your healthcare provider if you have any questions about your treatment with ACTEMRA.
Indication
ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well.
Important Safety Information
Some people have serious infections while taking ACTEMRA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.
Other serious side effects of ACTEMRA include tears (perforation) of the stomach and intestines, changes in blood test results, hepatitis B infection in those already carrying the virus, nervous system problems, and serious allergic reactions.
Common side effects with ACTEMRA include upper respiratory tract infections (common cold, sinus infections), headache, and increased blood pressure (hypertension).
Tell your healthcare provider if you plan to become pregnant or are pregnant. It is not known if ACTEMRA will harm your unborn baby. Genentech has a registry for pregnant women who take ACTEMRA. If you are pregnant or become pregnant while taking ACTEMRA, contact the registry at 1-877-311-8972 and talk to your healthcare provider.
Call your healthcare provider for medical advice about any side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-800-835-2555.
Please see full Prescribing Information and Medication Guide for additional important safety information.
Rituxan (Rituximab) INDICATIONS AND USAGE
Rheumatoid Arthritis
Rituxan is a prescription medication used to treat Rheumatoid Arthritis (RA) with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well enough.
People with serious infections should not receive Rituxan.
Rituxan Boxed WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.
Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.
For additional safety information, please see the full prescribing information, including Boxed WARNINGS and Medication Guide.
